

MEDIA RELEASE
20 December 2021

Kalapa Germany, acquires a minority stake in, and collaborates with, German Patient Support Program specialist

Health House International Ltd (ASX:HHI) (Health House or the Company or together with the entities it controls **the Group**), today announced its wholly-owned subsidiary Kalapa Germany (**Kalapa**) has entered into an agreement with German Patient Support Programmes specialist, 1Care Innohealth GmbH (**1Care**), to acquire a 5% minority stake and to collaborate in future related activities.

A Patient Support Programme (**PSP**) is a pharmaceutical industry best practice which provides support for patients in the use of medicine outside of their contact with their prescriber. A PSP gives additional support to prescribers who often don't have time to address patients' day-to-day needs. Patients can contact the PSP with enquiries between their regular doctors' appointments. A PSP allows the generation of data around the effects of the therapy and the improvement of quality of life.



Kalapa Germany has established the first PSP in the cannabis sector for patients prescribed, Group Company, CanPharma's products: CanPharma Care (www.canpharma-care.de).

Kalapa Germany Managing Director, Gesa Riedewald, said "We are happy to enter in this long-term collaboration with 1Care. We are in the process of developing an app which is to accompany the patients over the entire patient's journey which we will deploy through the PSP. We aim to digitalise the patient's journey and to process this data in order to optimise treatments for patients. The improvement of patients condition and well-being continues to be our top priority."

The CanPharma Care PSP will provide cannabis patients who are prescribed CanPharma products a 360-degree support via a telephone hotline after prescription, including:

- usage of the prescribed medicinal cannabis; and
- a coaching service and easy access to an expert.

The programme increases the chances of adherence of cannabis patients to their treatment, as they feel well accompanied through this new treatment and otherwise may stop using the product.

1Care has supported Kalapa Germany in the establishment of the CanPharma Care PSP. 1Care was founded by experts with many years' experience in setting up PSPs for pharmaceutical companies Teva Pharmaceuticals, Shire Deutschland and others indications including Multiple Sclerosis and Fabry disease.

"Treatment with medicinal cannabis patients differs from conventional pharmaceutical treatments, since it is far from standardised and the delivery system is often not familiar to them. Therefore, a PSP is ideal for cannabis patients as they may need ongoing support as they get accustomed to their treatment", said Founder and CEO of 1Care, Frank Bialkowski.

As part of the agreement, Kalapa Germany acquires a minority stake in 1Care in order to collaborate with 1Care in the future, especially when it comes to the generation of real - world evidence data and its usage for optimization of therapies.

Health House Chief Executive Officer, David Attwood said "The collaboration between 1Care and Kalapa Germany manifests the importance of the patient-centric approach for cannabis treatments. It all comes back to the data which are generated and can be used for product development and optimisation of treatments. The experience gained sets Kalapa Germany up to contribute to clinical trials."

About Health House

Health House International and the entities it controls (**the Group**) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

For more information, please visit www.healthhouse.com.au

Address

Level 3
101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au

Contact

David Attwood
Chief Executive Officer
David.attwood@healthhouse.com.au

David Wheeler

Chairman
david@pathwayscorporate.com.au